Animalcare (ANCR) AI Stock Analysis

• Market Cap: £171.09M
• Dividend Yield: 2.09%
• Average Volume (3M): 66.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 8.74%
• EPS Growth: -166.50%
• Country: UK
• Employees: 226
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.10
• Shares Outstanding: 68,989,075
• 10 Day Avg. Volume: 79,363
• 30 Day Avg. Volume: 66,930
• PEG Ratio: <0.01
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 12.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: 268.00p ▲(7.63% Upside)

Animalcare's overall stock score is primarily influenced by its strong financial performance, characterized by robust profitability and a stable balance sheet. However, technical indicators suggest bearish momentum, and valuation concerns arise due to a negative P/E ratio. The absence of earnings call insights and corporate events limits additional context for the stock's outlook.

Positive Factors

Cash Flow Generation

Strong cash flow generation supports financial flexibility, allowing Animalcare to invest in growth opportunities and manage liabilities effectively.

Balance Sheet Stability

A strong equity ratio and low debt-to-equity ratio reflect minimal leverage, providing Animalcare with resilience against financial downturns.

Profitability Improvement

Improved return on equity indicates effective cost management and profitability, enhancing shareholder value and supporting long-term growth.

Negative Factors

Rising Liabilities

Rising liabilities may strain financial resources and limit flexibility, potentially impacting Animalcare's ability to invest in growth.

Revenue Contraction

Revenue contraction suggests challenges in market expansion, which could hinder Animalcare's ability to capitalize on growth opportunities.

Negative Revenue Growth

Negative revenue growth reflects potential market share loss, posing a risk to Animalcare's competitive position and future profitability.

Animalcare Business Overview & Revenue Model

Company Description

Animalcare (ANCR) is a UK-based veterinary company focused on providing innovative healthcare solutions for pets and livestock. The company operates primarily in the animal health sector, developing, manufacturing, and marketing a broad range of veterinary pharmaceuticals, diagnostics, and other veterinary products. Animalcare's core offerings include prescription medicines, over-the-counter products, and veterinary services designed to enhance the health and well-being of animals.

How the Company Makes Money

Animalcare generates revenue through multiple streams, primarily by selling its veterinary pharmaceuticals and products to veterinary practices, pet owners, and livestock producers. The company has established a strong presence in the European market and partners with various distributors to enhance its product reach. Significant revenue is also derived from the sale of diagnostic tools and services that assist veterinarians in the treatment and management of animal health. Additionally, Animalcare invests in research and development to innovate and expand its product portfolio, which can lead to increased market share and revenue growth. Collaborations with research institutions and other healthcare companies further support its revenue generation efforts.

Animalcare Financial Statement Overview

Summary

Animalcare exhibits overall financial strength with robust profitability metrics and a stable balance sheet. The company has effectively managed its costs, resulting in improved net profit margins and return on equity. Despite slight revenue contraction, the company maintains strong cash flow generation capabilities, supporting its operational and financial strategies. However, attention should be given to the rising liabilities to sustain long-term financial health.

Income Statement

Animalcare has demonstrated stable revenue with a slight decrease in 2024. The gross profit margin remains strong at around 45.9% in 2024, reflecting efficient production. The net profit margin has significantly improved from previous years, reaching 43.4% in 2024, due to increased net income influenced by effective cost management. However, the revenue growth rate is negative over the past year, indicating a potential challenge in expanding market share.

Balance Sheet

The balance sheet shows a healthy equity ratio of 71.3% in 2024, indicating strong financial stability. The debt-to-equity ratio is low at 0.20, reflecting minimal leverage and low financial risk. Return on equity improved drastically to 28.4% in 2024, demonstrating enhanced profitability. However, the increase in total liabilities over the years could pose future risks if not managed effectively.

Cash Flow

Animalcare's cash flow statements reveal consistent free cash flow generation, with a growth rate of 51.7% from 2023 to 2024, supporting financial flexibility. The operating cash flow to net income ratio is robust at 0.37, indicating good cash conversion. However, the free cash flow to net income ratio is slightly lower at 0.36, suggesting some inefficiencies in cash utilization relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	81.07M	74.23M	74.35M	71.62M	74.02M	70.49M
Gross Profit	37.52M	34.06M	43.35M	40.66M	39.42M	36.56M
EBITDA	14.03M	13.43M	11.82M	11.04M	10.15M	10.30M
Net Income	2.98M	32.22M	1.20M	1.97M	-77.00K	234.00K
Balance Sheet
Total Assets	163.87M	158.81M	106.79M	118.24M	110.00M	124.44M
Cash, Cash Equivalents and Short-Term Investments	9.92M	11.71M	4.64M	6.04M	5.63M	5.26M
Total Debt	21.02M	24.01M	5.88M	11.44M	10.96M	18.88M
Total Liabilities	50.62M	45.50M	28.90M	39.26M	31.20M	42.84M
Stockholders Equity	113.25M	113.31M	77.89M	78.99M	78.80M	81.59M
Cash Flow
Free Cash Flow	11.12M	11.72M	7.73M	6.48M	10.81M	8.68M
Operating Cash Flow	11.41M	11.93M	10.28M	9.43M	14.02M	11.12M
Investing Cash Flow	-63.51M	-34.85M	-2.86M	-3.12M	-2.96M	-2.91M
Financing Cash Flow	29.22M	32.53M	-8.95M	-5.70M	-10.96M	-8.86M

Animalcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 249.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Positive. The current price of 249 is below the 20-day moving average (MA) of 249.05, above the 50-day MA of 242.91, and above the 200-day MA of 248.61, indicating a neutral trend. The MACD of 0.92 indicates Positive momentum. The RSI at 55.53 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ANCR.

Animalcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	70 Outperform	£66.40M	23.32	3.62%	―	1.44%	359.79%
HIK	67 Neutral	£3.89B	13.61	15.66%	4.03%	3.73%	27.13%
ANCR	57 Neutral	£171.09M	-7.00	2.83%	2.09%	8.74%	-166.50%
AGY	56 Neutral	£552.73M	―	―	―	4.50%	74.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Animalcare Corporate Events

Animalcare Group Reports Robust First-Half 2025 Performance with Strategic Growth Initiatives

Animalcare Group plc reported a strong first-half performance for 2025, with double-digit revenue and profit growth driven by the acquisition and integration of Randlab. Revenues increased by 18.5% to £43.8m, and underlying EBITDA grew by 39.5% to £9.2m. The company continues to invest in innovation and strategic opportunities, including a strategic equity stake in InVetro, to expand its presence in the Asia-Pacific region. The Group’s financial health supports ongoing M&A and R&D activities, with a focus on developing its product pipeline through partnerships and acquisitions, such as the VHH NGF antibody programme.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Collaborates with 272Bio to Develop Treatment for Equine ‘Sweet Itch’

Animalcare Group plc has announced a collaboration with 272Bio Limited to develop a novel biological treatment for ‘sweet itch,’ a common equine skin condition affecting around 8% of horses globally. This partnership aims to address the significant unmet need in the global equine health market, which is valued at €150m – €200m annually. The collaboration leverages Animalcare’s recent acquisition of the VHH NGF antibody program and strengthens its equine franchise, following the acquisition of Randlab. This initiative is part of Animalcare’s strategy to drive sustainable growth by bringing innovative products to market.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group to Announce H1 2025 Results and Host Presentations

Animalcare Group plc announced it will release its financial results for the first half of 2025 on 30 September 2025. The company will hold a virtual analyst presentation on the same day and an investor presentation on 6 October 2025, led by CEO Jenny Winter and CFO Chris Brewster. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Acquires VHH NGF Programme to Enhance Product Pipeline

Animalcare Group plc has acquired the VHH NGF programme and related assets from Orthros Medical for €0.7 million, gaining full control over the development and commercialization of the technology. This acquisition aligns with Animalcare’s strategy to build a pipeline of innovative products, particularly in the treatment of osteoarthritis-related pain in animals. The transaction eliminates future financial obligations under the previous license agreement and opens opportunities for further exploration of VHH technology across various species and diseases. Partnering with 272Bio, Animalcare is advancing its antibody programmes, which could provide access to some of the largest animal health markets globally.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Reports Strong H1 Revenue Growth Amid Strategic Expansion

Animalcare Group reported an 18.5% increase in H1 revenue, driven by strong performance from its newly acquired Australian equine business, Randlab, and growth in key products like Daxocox and Plaqtiv+. Despite challenges such as currency translation impacts and reduced sales of Conofite due to regulatory changes, the company remains optimistic about its strategic growth initiatives, including new product launches and international expansion, which are expected to enhance its market position and profitability.

The most recent analyst rating on (GB:ANCR) stock is a Buy with a £290.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.